Sabby Management, LLC
stated that they own a 8.3% stake in Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) in a Form 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Tuesday, March 13th. The investor owns 3,333,336 shares of the stock valued at approximately $5,300,004. The reporting parties listed on the disclosure included Sabby Healthcare Master Fund, Ltd, Sabby Volatility Warrant Master Fund, Ltd, Sabby Management, LLC and Hal Mintz. The disclosure is available through the SEC website at this hyperlink.
Shares of Can Fite Biopharma Ltd (NYSEAMERICAN CANF) traded up $0.02 during trading hours on Tuesday, hitting $1.59. The stock had a trading volume of 134,886 shares, compared to its average volume of 219,245. Can Fite Biopharma Ltd has a 1 year low of $1.24 and a 1 year high of $2.75. The company has a market capitalization of $32.28, a P/E ratio of 6.24 and a beta of 1.94.
CANF has been the subject of several analyst reports. Maxim Group set a $7.00 price target on Can Fite Biopharma and gave the company a “buy” rating in a report on Monday, December 18th. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Can Fite Biopharma in a report on Thursday, February 1st.
WARNING: “8.3% Stake of Can Fite Biopharma Ltd (CANF) Owned by Sabby Management, LLC” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3259970/8-3-stake-of-can-fite-biopharma-ltd-canf-owned-by-sabby-management-llc.html.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Want to see what other hedge funds are holding CANF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Can Fite Biopharma Ltd (NYSEAMERICAN:CANF).
Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.